PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
21091643-5	2011	KEY RESULTS: Delta9-THC decreased responding for both food presentation and stimulus-shock termination; these effects were antagonized by the CB1 antagonist rimonabant.	Dronabinol	13-23	cannabinoid receptor 1	Macaca mulatta	142-145	
22718500-4	2012	One potential explanation for atypical effects is CB1 receptor agonist efficacy, which is reportedly higher for JWH-018 and JWH-073 compared with Delta9-THC.	Dronabinol	146-156	cannabinoid receptor 1	Macaca mulatta	50-53	
22718500-8	2012	(1R,3R,4R)-3-[2-Hydroxy-4-(1,1-dimethylheptyl) phenyl]-4-(3-hydroxypropyl)cyclohexan-1-ol (CP-55,940), a prototype high-efficacy CB1 receptor agonist, JWH-018, and JWH-073 substituted for the discriminative stimulus effects of Delta9-THC.	Dronabinol	227-237	cannabinoid receptor 1	Macaca mulatta	129-132	
22718500-12	2012	The greater loss of sensitivity to Delta9-THC relative to CP-55,940 and JWH-018 suggests that differences in CB1 receptor agonist efficacy are important in vivo and might underlie differences in the dependence liability and adverse effects of synthetic CBs versus cannabis.	Dronabinol	35-45	cannabinoid receptor 1	Macaca mulatta	109-112	
21091643-11	2011	CONCLUSIONS AND IMPLICATIONS: In Delta9-THC-treated monkeys, the magnitude of tolerance and cross-tolerance to other CB1 receptor agonists varied inversely with agonist efficacy, suggesting that CB1 agonist efficacy is an important determinant of behavioural effects.	Dronabinol	40-43	cannabinoid receptor 1	Macaca mulatta	117-120	
21091643-11	2011	CONCLUSIONS AND IMPLICATIONS: In Delta9-THC-treated monkeys, the magnitude of tolerance and cross-tolerance to other CB1 receptor agonists varied inversely with agonist efficacy, suggesting that CB1 agonist efficacy is an important determinant of behavioural effects.	Dronabinol	40-43	cannabinoid receptor 1	Macaca mulatta	195-198	
16953389-0	2006	Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.	Dronabinol	111-138	cannabinoid receptor 1	Macaca mulatta	51-54	
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	172-199	cannabinoid receptor 1	Macaca mulatta	27-30	
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	172-199	cannabinoid receptor 1	Macaca mulatta	103-106	
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	201-211	cannabinoid receptor 1	Macaca mulatta	27-30	
16148440-1	2005	The prototypic cannabinoid CB1 antagonist SR 141716A is one important pharmacologic tool for examining CB1 receptors that mediate the behavioral and physiologic effects of delta9-tetrahydrocannabinol (delta9-THC).	Dronabinol	201-211	cannabinoid receptor 1	Macaca mulatta	103-106	
10780256-10	1999	In summary, CB1-receptor agonists such as delta 9-THC and WIN 55,212-2 were more disruptive to the rate and accuracy of learning in old-world monkeys than the CB1-receptor antagonist SR141716A or cannabidiol.	Dronabinol	42-53	cannabinoid receptor 1	Macaca mulatta	12-15